PIK3R2 and neoplasm: In our previous study, next-generation sequencing panel tests (Qiagen QIAseq Targeted DNA Panels)_of 27 tumor samples (13 in the AFTV group and 14 in the control group) [4] identified mutations in PIK3R2, also known as p85β, a Class I regulatory subunit of phosphatidylinositol 3-kinase (PI3K), as a potential prognostic factor (Supplementary Table 1).